C. Baba Et Al. , "Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study," ECTRIMS 2022 , vol.28, no.821, Amsterdam, Netherlands, pp.860, 2022
Baba, C. Et Al. 2022. Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study. ECTRIMS 2022 , (Amsterdam, Netherlands), 860.
Baba, C., Kaya, E., Özçelik, S., Özdoğar, A. T., Sağıcı, Ö., Daştan, S., ... Özakbaş, S.(2022). Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study . ECTRIMS 2022 (pp.860). Amsterdam, Netherlands
Baba, Cavid Et Al. "Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study," ECTRIMS 2022, Amsterdam, Netherlands, 2022
Baba, Cavid Et Al. "Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study." ECTRIMS 2022 , Amsterdam, Netherlands, pp.860, 2022
Baba, C. Et Al. (2022) . "Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study." ECTRIMS 2022 , Amsterdam, Netherlands, p.860.
@conferencepaper{conferencepaper, author={Cavid Baba Et Al. }, title={Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study}, congress name={ECTRIMS 2022}, city={Amsterdam}, country={Netherlands}, year={2022}, pages={860} }